The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes

AbstractThe prognostic value of peripheral blasts (PB) is not well-studied in patients with myelodysplastic syndromes (MDS). We evaluated the impact of PB on overall survival (OS) and transformation to acute myeloid leukemia (AML) in a large cohort. The MDS database at the Moffitt Cancer Center was retrospectively reviewed to identify patients with ≥ 1% PB (PB-MDS) and those without PB (BM-MDS). We also assessed the correlation between PB and gene mutations. One thousand seven hundred fifty-eight patients were identified, among whom 13% had PB near the time of diagnosis. PB-MDS patients were more likely to be younger with trilineage cytope nia, complex karyotype, higher-risk disease, transfusion dependence, and therapy-related MDS. The rate of AML transformation was 49 vs. 26% (p 
Source: Annals of Hematology - Category: Hematology Source Type: research

Related Links:

The integration of genetic data into the clinical and pathological assessment of myeloid neoplasms underscores the expanding role of genomic changes in the diagnosis, prognosis, classification and therapeutic implications of precision medicine. Myeloid neoplasms include myelodysplastic syndrome (MDS), myelodysplastic/ myeloproliferative neoplasm (MDS/MPN), myeloproliferative neoplasm (MPN) and acute myeloid leukemia (AML). The myelodysplastic syndromes (MDS) comprise a very heterogeneous group of clonal myeloid disorders characterized by peripheral blood cytopenias, a bone marrow aspirate/biopsy showing dysplasia in one or...
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Tags: Review Article Source Type: research
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractPurpose of ReviewTo review the diagnosis of individuals with hereditary hematopoietic malignancies (HHMs) that predispose to myelodysplastic syndrome and acute myeloid leukemia, barriers to HHM diagnosis, and unaddressed questions and controversies within the HHM field.Recent FindingsPathogenic germline mutations in approximately a dozen genes predispose to HHMs, and many more genes are likely to be involved. Many of these HHM genes have only been identified recently. HHM phenotypes are diverse, but may be categorized as “purely” myeloid syndromes, syndromes with abnormal platelet number/function, and H...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS has been hampered by evolving diagnostic criteria and delayed classification of MDS as cancers until 2001. The poorly-understood nature of these neoplasms combined with the lack of effective therapies for decades contributed to suboptimal case ascertainment and underreporting.
Source: Blood Reviews - Category: Hematology Authors: Tags: Review Source Type: research
This article summarizes the milestones in the development of ivosidenib leading to this first approval in the USA for the treatment of patients with relapsed or refractory AML with a susceptibleIDH1 mutation. Clinical development for AML, cholangiocarcinoma, glioma, myelodysplastic syndromes and solid tumours is ongoing worldwide.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Bu... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: August 2018Source: Seminars in Cancer Biology, Volume 51Author(s): Linn Gillberg, Andreas D. Ørskov, Minmin Liu, Laurine B.S. Harsløf, Peter A. Jones, Kirsten GrønbækAbstractOver the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their central r...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: August 2018Source: The Lancet Haematology, Volume 5, Issue 8Author(s): Subhayan Chattopadhyay, Guoqiao Zheng, Amit Sud, Hongyao Yu, Kristina Sundquist, Jan Sundquist, Asta Försti, Akseli Hemminki, Richard Houlston, Kari HemminkiSummaryBackgroundAlthough advances in the treatment of myeloid neoplasms have led to improved patient survival, this improvement has been accompanied by an increased risk of second primary cancer (ie, the risk of another cancer after myeloid neoplasia). We aimed to assess bi-directional associations between myeloid cancers and other cancers—ie, development of second prim...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Myelodysplastic syndrome (MDS) is a disease caused by an ineffective hematopoiesis. MDS can develop into acute myeloid leukemia (AML), an aggressive blood cancer of the myeloid lineage. AML patients have a poor prognosis despite treatment with intensive chemotherapy, hence alternative therapies are needed.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Hematology | Leukemia | Myelodysplastic Syndrome